Market Report Source

Overview

The Asian Cardiovascular Market Outlook to 2010 is a new management report which provides comprehensive coverage of the major cardiovascular markets in the Asia Pacific region. This report provides detailed analysis of, market trends, epidemiology, current leading brands of treatment, product sales forecast and future market leaders over the period 2005-2010 in nine markets: China, India, Singapore, South Korea, Thailand, Philippines, Malaysia, Indonesia and Taiwan. The Asia Pacific region is an important market for cardiovascular products; it is estimated to have high prevalence rates for cardiovascular diseases and associated risk factors. However, due to the increasing presence of effective generic medicine and the limited launches of innovative, the threat of underperformance facing major pharmaceutical companies is now very real. Through analysis and forecasts ,this report will allow you to identify the cardiovascular market trends in developed and emerging Asian countries, assess the dominant forces driving market growth and develop potential growth and diversification opportunities in this region over the period 2005-2010.

Table of Contents

Table of Contents

The Asian Cardiovascular Market Outlook to

Executive Summary

Patient potential

Regional healthcare and licensing trends

Regional market analysis

Key players in the Asian cardiovascular market

Chapter 1 Patient potential

Summary

Introduction

Disease description

Defining patient potential

Limitations of cardiovascular epidemiology data

Cardiovascular risk factors

Hypertension

Dyslipidemia

Diabetes

Cardiovascular disease

Acute thrombotic events

Acute coronary syndromes

Venous thromboembolism

Stroke

Chapter 2 Regional healthcare and licensing

trends

Summary

Introduction

Regional healthcare expenditure

Healthcare financing

iv

The external environment

Licensing analysis

Chapter 3 Regional market analysis

Summary

Introduction

Market breakdown by therapy area

Market breakdown by country

Leading products

Anti-hypertensives

Introduction

Analysis of the top 10 anti-hypertensives

Regional dynamics

Market analysis by drug class

ACE inhibitors

Angiotensin receptor blockers

Beta-blockers

Calcium channel blockers

Diuretics

Anti-hypertensives sales forecasts

Anti-dyslipidemics

Introduction

Analysis of the top 10 anti-dyslipidemics

Regional dynamics

Market analysis by drug class

Statins

Fibrates

Other anti-dyslipidemics

Anti-dyslipidemics sales forecast

Cardiac therapies

Introduction

Analysis of the top 10 cardiac therapy brands

Regional dynamics

Market analysis by drug class

Nitrates/nitrites

Anti-arrhythmics

Others

Cardiac therapies sales forecasts

Anti-thrombotics

Introduction

Analysis of the top 10 anti-thrombotics

Regional dynamics

Market analysis by drug class

Heparins/low molecular weight heparins

v

Vitamin K antagonists

Oral anti-platelets

Fibrinolytics

Anti-thrombotic sales forecasts

Chapter 4 Key players in the Asian

cardiovascular market

Summary

Introduction

Asian market shares

Pfizer

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Sanofi-Aventis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Merck & Co

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

AstraZeneca

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Novartis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Bayer

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

GSK

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Roche

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

vi

Chapter 5 Appendix

IMS sales data

Glossary

Index

List of Figures

Figure 1.1: Relationship between cardiovascular disease and risk factors

Figure 1.2: Risk factors associated with hypertension

Figure 2.3: External analysis of the Asian region

Figure 3.4: Competitive dynamics in the Asian cardiovascular market,

Figure 3.5: Competitive dynamics the top 10 selling cardiovascular products in the cardiovascular

market, 2003–04

Figure 3.6: Competitive dynamics of the Asian anti-hypertensive market by drug class, 2003–0

Figure 3.7: Competitive dynamics the top 10 selling anti-hypertensives in the Asian region, 2003–

04

Figure 3.8: Competitive dynamics in the Asian anti-dyslipidemics market, 2003–04

Figure 3.9: Competitive dynamics the top 10 selling anti-dyslipidemics in the Asian region, 2003–

04

Figure 3.10: Competitive dynamics in the Asian cardiac therapy market by drug class, 2003–04

Figure 3.11: The competitive dynamics of leading brands in the cardiac therapy area in the Asian

region, 2003–04

Figure 3.12: Competitive dynamics in the Asian anti-thrombotic market by drug class, 2003–04

Figure 3.13: Competitive dynamics of the top ten leading brands in the anti-thrombotics market,

2003–04

Figure 4.14: Market share of key players in the Asian cardiovascular market, 2000 and 2004

List of Tables

Table 1.1: Estimated prevalence of hypertension in the Asian region, 2004

Table 1.2: Estimated prevalence of hypertension in the Asian region, 2005–10

Table 1.3: Clinical guidelines for adult patients at borderline and high risk of cardiovascular

disease by serum levels of lipids

Table 1.4: Estimated prevalence of hypercholesterolemia in the Asian region, 2004

Table 1.5: Estimated forecast prevalence of hypercholesterolemia in the Asian region, 2005–

Table 1.6: Estimated prevalence of diabetes in the Asian region, 2004

Table 1.7: Estimated prevalence of diabetes in the Asian region, 2005–10

Table 1.8: Estimated prevalence of major cardiovascular diseases in the Asian region, 2004

Table 1.9: Estimated incidence of myocardial infarction (MI) in the Asian region, 2004

Table 1.10: Estimated incidence of DVT in the Asian region, 2004

Table 1.11: Estimated prevalence of stroke in the Asian region, 2004

Table 2.12: Recent statistics on the healthcare sector in the Asian region, 2002

vii

Table 2.13: Public and private financing in nine Asian markets, 2002

Table 2.14: Sales of types of cardiovascular brands in the Asian pharmaceutical market, 2000-

Table 2.15: Sales of types of cardiovascular brands in the nine major markets of the Asian region,

2004

Table 3.16: Breakdown of the Asian cardiovascular market by major therapeutic areas, 2000–04

Table 3.17: Cardiovascular sales by therapy area across the Asian region, 2004

Table 3.18: Top 10 selling branded cardiovascular products in the Asian market, 2004

Table 3.19: Breakdown of Asian anti-hypertensive market by drug class, 2000–04

Table 3.20: Breakdown of the Asian anti-hypertensive market by leading brands, 2003–04

Table 3.21: Market share of the leading classes of anti-hypertension drugs in the Asian region,

2004

Table 3.22: Market share of the ACE inhibitor/ARB category in the Asian region, 2004

Table 3.23: Breakdown of the ACE inhibitor class in the Asian market by leading brands, 2003–

Table 3.24: Breakdown of the ARB drug class in the Asian market by leading brands, 2003–04

Table 3.25: Market share of the beta blockers drug class in the Asian region, 2004

Table 3.26: Breakdown of the beta-blocker class in the Asian market by leading brands, 2003–

Table 3.27: Market share of the CCB drug class in the Asian region, 2004

Table 3.28: Breakdown of the CCB class in the Asian market by leading brands, 2003–04

Table 3.29: Market share of the diuretic drug class in the Asian region, 2004

Table 3.30: Breakdown of the diuretic class in the Asian market by leading brands, 2003–04

Table 3.31: Sales forecasts for hypertension drug classes in the major markets of the Asian region,

2004–10

Table 3.32: Breakdown of the Asian anti-dyslipidemic market by drug class, 2000–04

Table 3.33: Breakdown of the Asian anti-dyslipidemic market by leading brands, 2003–04

Table 3.34: Market share of dyslipidemia class of drugs in the nine major markets of the Asian

region, 2004

Table 3.35: Sales forecasts for dyslipidemia drug classes in the Asian region, 2004–10

Table 3.36: Breakdown of the Asian cardiac therapy market by drug class, 2000–04

Table 3.37: Breakdown of the Asian cardiac therapy market by leading brands, 2003–04

Table 3.38: Market share of cardiac therapy class drugs in the nine major markets of the Asian

region, 2004

Table 3.39: Sales forecasts for cardiac therapies drug classes in the Asian region, 2004–10

Table 3.40: Breakdown of the Asian anti-thrombotic market by drug class, 2000–04

Table 3.41: Breakdown of the Asian region anti-thrombotic market by leading brands, 2004–

Table 3.42: Market share of anti-thrombotics class of drugs in the nine major markets of the Asian

region, 2004

Table 3.43: Sales forecast for the anti-thrombotic drug class in the Asian region, 2004–10

Table 4.44: Key players in the Asian cardiovascular market, 2000–2004

Table 4.45: Pfizer’s marketed Asian cardiovascular portfolio, 2004

Table 4.46: Pfizer’s cardiovascular R&D pipeline, 2005

Table 4.47: Forecast sales for Pfizer’s Asian cardiovascular portfolio, 2004–10

Table 4.48: Sanofi-Aventis’ marketed Asian cardiovascular portfolio, 2004

Table 4.49: Sanofi-Aventis’ cardiovascular R&D pipeline, 2005

Table 4.50: Forecast sales for Sanofi-Aventis’ Asian cardiovascular portfolio, 2004–10

Table 4.51: Merck & Co.’s marketed Asian cardiovascular portfolio, 2004

Table 4.52: Merck & Co.’s cardiovascular R&D pipeline, 2005

Table 4.53: Forecast sales for Merck & Co.’s Asian cardiovascular portfolio, 2004–10

Table 4.54: AstraZeneca’s marketed Asian cardiovascular portfolio, 2004

Table 4.55: AstraZeneca’s cardiovascular R&D pipeline, 2005

Table 4.56: Forecast sales for AstraZeneca’s Asian cardiovascular portfolio, 2004–10

viii

Table 4.57: Novartis’ marketed Asian cardiovascular portfolio, 2004

Table 4.58: Novartis’ cardiovascular R&D pipeline, 2005

Table 4.59: Forecast sales for Novartis’ Asian cardiovascular portfolio, 2004–10

Table 4.60: Bayer’s marketed Asian cardiovascular portfolio, 2004

Table 4.61: Bayer’s cardiovascular R&D pipeline, 2005

Table 4.62: Forecast sales for Bayer’s Asian cardiovascular portfolio, 2004–10

Table 4.63: GSK’s marketed Asian cardiovascular portfolio, 2004

Table 4.64: GSK’s cardiovascular R&D pipeline, 2005

Table 4.65: Forecast sales for GSK’s Asian cardiovascular portfolio, 2004–10

Table 4.66: Roche’s marketed Asian cardiovascular portfolio, 2004

Table 4.67: Roche’s cardiovascular R&D pipeline, 2005

Table 4.68: Forecast sales for Roche’s Asian cardiovascular portfolio, 2004–10 169